CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Astellas Pharma Inc. - 4503 CFD

1660.65
0.91%
Market Trading Hours* (UTC) Opens on Tuesday at 00:00

Mon - Fri: 00:00 - 02:30 03:30 - 06:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 14.70
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.011013 %
Charges from full value of position ($-2.09)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.011013%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.011209 %
Charges from full value of position ($-2.13)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.011209%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency JPY
Margin 5%
Stock exchange Japan
Commission on trade 0%

*Information provided by Capital.com

Astellas Pharma Inc ESG Risk Ratings

High Medium Low Negligible

‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly

More ESG coverage

Key Stats
Prev. Close* 1645.69
Open* 1643.69
1-Year Change* -13.81%
Day's Range* 1642.7 - 1672.62
52 wk Range 1,600.50-2,360.50
Average Volume (10 days) 8.46M
Average Volume (3 months) 165.66M
Market Cap 3,106.29B
P/E Ratio 91.75
Shares Outstanding 1.79B
Revenue 1,523.57B
EPS 18.71
Dividend (Yield %) 3.78678
Beta 0.75
Next Earnings Date Feb 5, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 26, 2024 1664.25 10.98 0.66% 1653.27 1673.62 1642.19
Feb 22, 2024 1643.69 -22.05 -1.32% 1665.74 1665.74 1639.71
Feb 21, 2024 1673.22 -10.37 -0.62% 1683.59 1684.69 1668.13
Feb 20, 2024 1683.19 5.58 0.33% 1677.61 1690.68 1673.61
Feb 19, 2024 1673.62 3.00 0.18% 1670.62 1685.69 1665.24
Feb 16, 2024 1667.63 6.98 0.42% 1660.65 1677.11 1645.19
Feb 15, 2024 1647.29 -1.89 -0.11% 1649.18 1654.77 1631.72
Feb 14, 2024 1662.75 13.57 0.82% 1649.18 1664.74 1638.71
Feb 13, 2024 1649.78 33.41 2.07% 1616.37 1649.78 1610.74
Feb 9, 2024 1610.88 17.45 1.10% 1593.43 1616.77 1586.84
Feb 8, 2024 1585.82 -18.08 -1.13% 1603.90 1614.87 1584.34
Feb 7, 2024 1616.27 13.87 0.87% 1602.40 1624.25 1601.29
Feb 6, 2024 1620.06 -62.53 -3.72% 1682.59 1693.17 1616.27
Feb 5, 2024 1690.57 26.43 1.59% 1664.14 1697.06 1664.14
Feb 2, 2024 1674.61 -21.25 -1.25% 1695.86 1697.66 1673.12
Feb 1, 2024 1684.69 -4.89 -0.29% 1689.58 1695.76 1673.12
Jan 31, 2024 1722.09 17.05 1.00% 1705.04 1724.59 1698.55
Jan 30, 2024 1707.53 -5.69 -0.33% 1713.22 1725.99 1707.03
Jan 29, 2024 1708.83 14.07 0.83% 1694.76 1716.71 1681.76
Jan 26, 2024 1680.60 -3.09 -0.18% 1683.69 1688.78 1668.73

Astellas Pharma Inc. Events

Time (UTC) Country Event
Thursday, March 28, 2024

Time (UTC)

12:00

Country

JP

Event

Astellas Pharma Inc
Astellas Pharma Inc

Forecast

-

Previous

-
Thursday, April 25, 2024

Time (UTC)

06:00

Country

JP

Event

Full Year 2024 Astellas Pharma Inc Earnings Release
Full Year 2024 Astellas Pharma Inc Earnings Release

Forecast

-

Previous

-
Friday, June 21, 2024

Time (UTC)

01:00

Country

JP

Event

Astellas Pharma Inc Annual Shareholders Meeting
Astellas Pharma Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total revenue 1518620 1296160 1249530 1300840 1306350
Revenue 1518620 1296160 1249530 1300840 1306350
Cost of Revenue, Total 288353 253009 246063 276739 292050
Gross Profit 1230270 1043150 1003460 1024100 1014300
Total Operating Expense 1390600 1135390 1102920 1056850 1062440
Selling/General/Admin. Expenses, Total 630272 548840 504316 499295 490263
Research & Development 276128 246010 224489 224226 208682
Depreciation / Amortization 38436 28283 23763 21164 35212
Interest Expense (Income) - Net Operating 8864 -8661 1854 10588 892
Unusual Expense (Income) 94766 66036 102469 12903 43425
Other Operating Expenses, Total 53778 1876 -35 11937 -8088
Operating Income 128022 160770 146609 243991 243912
Interest Income (Expense), Net Non-Operating 2035 -1454 -1358 16 1468
Other, Net 2304 -2430 73 1343 3587
Net Income Before Taxes 132361 156886 145324 245350 248967
Net Income After Taxes 98714 124086 120590 195411 222265
Net Income Before Extra. Items 98714 124086 120590 195411 222265
Net Income 98714 124086 120590 195411 222265
Total Adjustments to Net Income -1
Income Available to Common Excl. Extra. Items 98714 124086 120589 195411 222265
Income Available to Common Incl. Extra. Items 98714 124086 120589 195411 222265
Diluted Net Income 98714 124086 120589 195411 222265
Diluted Weighted Average Shares 1825.06 1850.6 1857.12 1877.55 1933.74
Diluted EPS Excluding Extraordinary Items 54.0881 67.0517 64.9332 104.078 114.94
Dividends per Share - Common Stock Primary Issue 60 50 42 40 38
Diluted Normalized EPS 92.8133 95.2749 110.718 109.551 134.988
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 354254 402180 380394 381791 303870
Revenue 354254 402180 380394 381791 303870
Cost of Revenue, Total 62280 74422 62781 88870 58915
Gross Profit 291974 327758 317613 292921 244955
Total Operating Expense 402504 340792 293650 348644 317555
Selling/General/Admin. Expenses, Total 159295 163022 154560 153396 142420
Research & Development 70076 66875 65170 74007 68362
Depreciation / Amortization 9262 9207 9223 10745 8036
Interest Expense (Income) - Net Operating 111 407 -1429 -14432 1543
Other Operating Expenses, Total 36769 25904 18423 -1616 -5512
Operating Income -48250 61388 86744 33147 -13685
Interest Income (Expense), Net Non-Operating 372 -1630 2057 -1469 3168
Other, Net 1 1 1
Net Income Before Taxes -47877 59758 88801 31679 -10516
Net Income After Taxes -46125 48405 71622 24812 -8408
Net Income Before Extra. Items -46125 48405 71622 24812 -8408
Net Income -46125 48405 71622 24812 -8408
Total Adjustments to Net Income 1 -1
Income Available to Common Excl. Extra. Items -46125 48405 71623 24812 -8409
Income Available to Common Incl. Extra. Items -46125 48405 71623 24812 -8409
Diluted Net Income -46125 48405 71623 24812 -8409
Diluted Weighted Average Shares 1809.69 1823.49 1823.38 1825.05 1840.23
Diluted EPS Excluding Extraordinary Items -25.4878 26.5453 39.2803 13.5952 -4.56954
Dividends per Share - Common Stock Primary Issue 30 0 30 0 25
Diluted Normalized EPS -2.24506 26.9695 32.6108 29.7633 10.8982
Unusual Expense (Income) 64711 955 -15078 37674 43791
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total Current Assets 1049950 923354 872588 867514 857159
Cash and Short Term Investments 376946 318267 326128 324943 311074
Cash & Equivalents 376840 315986 326128 313126 297477
Short Term Investments 106 2281 11817 13597
Total Receivables, Net 465455 423018 362722 373505 365348
Accounts Receivable - Trade, Net 427965 382462 343178 347042 342628
Total Inventory 174386 153072 164080 151017 151511
Prepaid Expenses 12743
Other Current Assets, Total 33167 28997 19658 18049 16483
Total Assets 2456520 2332400 2273630 2315170 1897650
Property/Plant/Equipment, Total - Net 286459 269044 264623 268600 173483
Property/Plant/Equipment, Total - Gross 660838 624055 592329 564186 448245
Accumulated Depreciation, Total -374379 -355010 -327707 -295586 -274762
Goodwill, Net 328411 303030 284011 278253 225864
Intangibles, Net 562496 623431 651427 724773 429707
Long Term Investments 101955 91009 91704 66399 75462
Note Receivable - Long Term 32793 40666 45188 46570 34912
Other Long Term Assets, Total 94450 81861 64087 63060 101061
Total Current Liabilities 726034 687411 592372 798708 497665
Accounts Payable 140236 130739 124777 171954 185280
Notes Payable/Short Term Debt 75000 140000 120000 326000 0
Current Port. of LT Debt/Capital Leases 13546 17730 16101 18105 430
Other Current Liabilities, Total 497252 398942 331494 282649 311955
Total Liabilities 948564 872087 887513 1026000 639252
Total Long Term Debt 111461 55014 142163 129272 52882
Long Term Debt 50000 0 80000 60045 52113
Capital Lease Obligations 61461 55014 62163 69227 769
Deferred Income Tax 6048 5823 18161 24670 5175
Other Liabilities, Total 105021 123839 134817 73351 83530
Total Equity 1507950 1460310 1386120 1289170 1258400
Common Stock 103001 103001 103001 103001 103001
Additional Paid-In Capital 181280 179467 177830 177506 177301
Retained Earnings (Accumulated Deficit) 908694 944891 954034 906750 993084
Treasury Stock - Common -25123 -13934 -15377 -7178 -164629
Unrealized Gain (Loss)
Other Equity, Total 340102 246883 166627 109089 149639
Total Liabilities & Shareholders’ Equity 2456520 2332400 2273630 2315170 1897650
Total Common Shares Outstanding 1796.76 1827.07 1853.03 1857.51 1885.84
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 1116760 1317450 1049950 1072590 1059140
Cash and Short Term Investments 363649 602813 376947 413296 393020
Cash & Equivalents 333993 561487 376840 381816 361073
Total Receivables, Net 504603 477214 465455 462945 463507
Accounts Receivable - Trade, Net 487893 462503 427965 451275 452485
Total Inventory 213648 200224 174386 163221 168636
Other Current Assets, Total 34856 37203 33166 33131 33982
Total Assets 3543020 2797960 2456520 2513950 2583660
Property/Plant/Equipment, Total - Net 296555 290784 286459 269106 280552
Property/Plant/Equipment, Total - Gross 660838
Accumulated Depreciation, Total -374379
Goodwill, Net 403822 355683 328411 324068 353095
Intangibles, Net 1532550 590424 562496 616538 653629
Long Term Investments 118637 110495 101955 102703 102268
Note Receivable - Long Term 21693 22955 32793 24804 26688
Other Long Term Assets, Total 53007 110163 94450 104136 108284
Total Current Liabilities 1162260 991494 726034 705905 761412
Accounts Payable 147250 138439 140236 134235 146533
Notes Payable/Short Term Debt 0 0 75000 0 0
Current Port. of LT Debt/Capital Leases 416558 309000 13546 180413 205611
Other Current Liabilities, Total 598451 544055 497252 391257 409268
Total Liabilities 1903680 1219540 948564 943524 934143
Total Long Term Debt 473054 50000 111461 148738 82391
Long Term Debt 473054 50000 50000 148738 82391
Capital Lease Obligations 61461
Deferred Income Tax 92673 6539 6048 6033 6104
Other Liabilities, Total 175690 171508 105021 82848 84236
Total Equity 1639340 1578420 1507950 1570420 1649520
Common Stock 103001 103001 103001 103001 103001
Additional Paid-In Capital 182148 180640 181280 180591 180147
Retained Earnings (Accumulated Deficit) 885006 885027 908694 996847 1004190
Treasury Stock - Common -34417 -34476 -25123 -23020 -23325
Other Equity, Total 503607 444225 340102 313005 385503
Total Liabilities & Shareholders’ Equity 3543020 2797960 2456520 2513950 2583660
Total Common Shares Outstanding 1792.87 1792.84 1796.76 1822.81 1822.61
Short Term Investments 29656 41326 107 31480 31947
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Net income/Starting Line 132361 156886 145324 245350 248967
Cash From Operating Activities 327767 257443 306843 221997 256899
Cash From Operating Activities 105738 79684 72652 66396 63458
Non-Cash Items 85167 73650 91075 12437 6391
Cash Taxes Paid 69479 42093 17870 47993 69913
Changes in Working Capital 4501 -52777 -2208 -102186 -61917
Cash From Investing Activities -84500 -62413 -81894 -389793 -41757
Capital Expenditures -88541 -76448 -77441 -77888 -52128
Other Investing Cash Flow Items, Total 4041 14035 -4453 -311905 10371
Cash From Financing Activities -195623 -216298 -229479 181055 -233681
Financing Cash Flow Items -3217 -2530 -2268 -847 -1173
Total Cash Dividends Paid -100355 -85236 -76157 -73539 -72066
Issuance (Retirement) of Stock, Net -60556 -50717 -9163 -52899 -160442
Foreign Exchange Effects 13210 11125 12267 -5942 -2118
Net Change in Cash 60854 -10143 7737 7317 -20657
Issuance (Retirement) of Debt, Net -31495 -77815 -141891 308340
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 132361 180238 120480 31679 156886
Cash From Operating Activities 327767 212174 139857 48832 257443
Cash From Operating Activities 105738 82721 59724 36872 79684
Non-Cash Items 85167 25277 22179 23503 73650
Cash Taxes Paid 69479 58160 35195 32688 42093
Changes in Working Capital 4501 -76062 -62526 -43222 -52777
Cash From Investing Activities -84500 -61781 -34660 -19144 -62413
Capital Expenditures -88541 -60422 -39689 -18259 -76448
Other Investing Cash Flow Items, Total 4041 -1359 5029 -885 14035
Cash From Financing Activities -195623 -91120 -81431 -46602 -216298
Financing Cash Flow Items -3217 -2277 -1348 -682 -2530
Total Cash Dividends Paid -100355 -100355 -45677 -45677 -85236
Issuance (Retirement) of Stock, Net -60556 -10555 -10553 -10553 -50717
Issuance (Retirement) of Debt, Net -31495 22067 -23853 10310 -77815
Foreign Exchange Effects 13210 6557 21321 13941 11125
Net Change in Cash 60854 65830 45087 -2973 -10143
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Nomura Asset Management Co., Ltd. Investment Advisor 5.9032 106827194 -694900 2023-09-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 4.3851 79356410 -19511080 2022-07-29 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.9679 53708611 190400 2023-09-30 LOW
Nippon Life Insurance Company Insurance Company 2.8507 51588000 0 2023-03-31 LOW
Daiwa Asset Management Co., Ltd. Investment Advisor 2.827 51158505 -107724 2023-09-30 LOW
Mitsubishi UFJ Trust and Banking Corporation Bank and Trust 2.8249 51120500 -6301500 2023-10-09 LOW
Nikko Asset Management Co., Ltd. Investment Advisor/Hedge Fund 2.8196 51026019 306800 2023-09-30 LOW
BlackRock Japan Co., Ltd. Investment Advisor 2.4782 44846700 34108000 2023-07-31 LOW
BlackRock Fund Advisors Investment Advisor 1.9467 35228415 35177015 2023-07-31 MED
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.7155 31045089 -6002277 2023-07-31 LOW
Mitsubishi UFJ Kokusai Asset Management Co., Ltd. Investment Advisor 1.581 28611000 5746711 2023-10-09 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.5202 27511025 4163025 2022-12-31 LOW
JPMorgan Securities Japan Co., Ltd. Research Firm 1.0617 19213000 425000 2023-03-31 LOW
T. Rowe Price Associates, Inc. Investment Advisor 0.9474 17144300 1187800 2023-09-30 LOW
BlackRock Asset Management Ireland Limited Investment Advisor 0.788 14260460 14260460 2023-07-31 LOW
BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 0.6946 12570120 218500 2023-09-30 LOW
California Public Employees' Retirement System Pension Fund 0.6664 12059534 579600 2022-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.6468 11704695 3500 2023-09-30 LOW
Lindsell Train Limited Investment Advisor/Hedge Fund 0.5882 10645200 -370000 2023-09-30 LOW
FIL Investments (Japan) Limited Investment Advisor 0.5588 10111685 5000 2023-09-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Astellas Pharma Inc. Company profile

About Astellas Pharma Inc

Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

Financial summary

BRIEF: For the nine months ended 31 December 2021, Astellas Pharma Inc revenues increased 5% to Y992.29B. Net income applicable to common stockholders decreased less than 1% to Y132.49B. Revenues reflect Sales of Pharmaceuticals segment increase of 6% to Y971.11B, Other Business segment increase of 33% to Y14.07B, Americas segment increase of 15% to Y407.94B, Estabridge segment increase of 10% to Y239.22B.

Equity composition

04/2005, Company merged with Fujisawa Pharmaceutical Co., Ltd. & Name Changed from Yamanouchi Pharmaceutical Co., Ltd. FY'08 1Q&Q3 WAS & DWAS estimated and WAS used as O/S. FY'09 Q3,12 Q2 DWAS estimated.

Industry: Pharmaceuticals (NEC)

日本橋本町2-5-1
CHUO-KU
TOKYO-TO 103-8411
JP

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

US100

17,980.90 Price
+0.310% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

54,739.55 Price
+5.480% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

2,032.19 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0189%
Short position overnight fee 0.0106%
Overnight fee time 22:00 (UTC)
Spread 0.30

Oil - Crude

77.60 Price
+1.390% 1D Chg, %
Long position overnight fee 0.0054%
Short position overnight fee -0.0273%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading